NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Stanford University
University of California, San Francisco
UNC Lineberger Comprehensive Cancer Center
Clinical Research Center for Solid Tumor, Korea